CLASSIC IMMUNOTOXINS WITH PLANT OR MICROBIAL TOXINS - Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges - page 280

81. Ghetie V, Thorpe P, Ghetie MA, Knowles P, Uhr JW, Vitetta
ES. (1991) The GLP large scale preparation of immunotoxins
containing deglycosylated ricin A chain and a hindered
disulfide bond. J. Immunol. Methods 142, 223-230.
82. Grossbard ML, Lambert JM, Goldmacher VS, Spector NL,
Kinsella J, Eliseo L, et al. (1993) Anti-B4-blocked ricin:
a Phase I trial of 7-day continuous infusion in patients with
B-cell neoplasms. J. Clin. Oncol. 11, 726-737.
83. Myers DE, Irvin JD, Smith RS, Kuebelbeck VM, Uckun FM.
(1991) Production of a pokeweed antiviral protein (PAP)-
containing immunotoxin, B43-PAP, directed against the
CD19 human B lineage lymphoid differentiation antigen in
highly purified form for human clinical trials. J. Immunol.
Methods 136, 221-237.
84. Flavell DJ, Flavell SU, Boehm DA, Emery L, Noss A, Ling
NR. (1995) Preclinical studies with the anti-CD19-saporin
immunotoxin BU12-SAPORIN for the treatment of human-
B-cell tumours. Br. J. Cancer 72, 1373-1379.
85. Winkler U, Gottstein C, Schon G, Kapp U, Wolf J, Hansmann
ML. (1994) Successful treatment of disseminated human
Hodgkin's disease in SCID mice with deglycosylated ricin
A-chain immunotoxins. Blood 83, 466-475.
86. Engert A, Diehl V, Schnell R, Radszuhn A, Hatwig MT,
Drillich S, et al. (1997) A Phase-I study of an anti-CD25 ricin
A-chain immunotoxin (RFT5-SMPT-dgA) in patients with
refractory Hodgkin's lymphoma. Blood 89, 403-410.
87. Oratz R, Speyer JL, Wernz JC, Hochster H, Meyers M,
Mischak R. (1990) Antimelanoma monoclonal antibody-ricin
A chain immunoconjugate (XMMME-001-RTA) plus cyclo-
phosphamide in the treatment of metastatic malignant mela-
noma: results of a Phase II trial. J. Biol. Response Mod. 9,
345-354.
88. Spitler LE, del Rio M, Khentigan A, Wedel NI, Brophy NA,
Miller LL, et al. (1987) Therapy of patients with malignant
melanoma using a monoclonal antimelanoma antibody-ricin
A chain immunotoxin. Cancer Res. 47, 1717-1723.
89. Scannon PJ, Spitler LE, Lee HM, Kawahata RT, Mischak PR.
(1986) Human melanoma specific immunotoxins. United
States Patent, 4590071.
90. Bjorn MJ, Ring D, Frankel A. (1985) Evaluation of mono-
clonal antibodies for the development of breast cancer immu-
notoxins. Cancer Res. 45, 1214-1221.
91. Weiner LM, O'Dwyer J, Kitson J, Comis RL, Frankel AE,
Bauer RJ. (1989) Phase I evaluation of an anti-breast carci-
noma monoclonal antibody 260F9-recombinant ricin A chain
immunoconjugate. Cancer Res. 49, 4062-4067.
92. Falini B, Bolognesi A, Flenghi L, Tazzari PL, Broe MK, Stein
H, et al. (1992) Response of refractory Hodgkin's disease to
monoclonal anti-CD30 immunotoxin. Lancet 339, 1195-1196.
93. Tazzari PL, Bolognesi A, de Totero D, Falini B, Lemoli RM,
Soria MR, et al. (1992) Ber-H2 (anti-CD30)-saporin immu-
notoxin: a new tool for the treatment of Hodgkin's disease
and CD30 þ lymphoma: in vitro evaluation. Br. J. Haematol.
81, 203-211.
94. Dean A, Talpaz M, Kantarjian H, Faderl S, Jabbour E,
FKashani FR. (2010) Phase I clinical trial of the anti-CD33

immunotoxin HuM195/rgel in patients (pts) with advanced
myeloid malignancies. J. Clin. Oncol. 28, 6549.
95. Pagliaro LC, Liu B, Munker R, Andreeff M, Freireich EJ,
Scheinberg DA. (1998) Humanized M195 monoclonal anti-
body conjugated to recombinant gelonin: an anti-CD33
immunotoxin with antileukemic activity. Clin. Cancer Res.
4, 1971-1976.
96. Batra JK, Jinno Y, Chaudhary VK, Kondo T, WillinghamMC,
FitzGerald DJ. (1989) Antitumor activity in mice of an
immunotoxin made with anti-transferrin receptor and a
recombinant form of Pseudomonas exotoxin. Proc. Natl.
Acad. Sci. USA 86, 8545-8549.
97. Johnson VG, Wilson D, Greenfield L, Youle RJ. (1988) The
role of the diphtheria toxin receptor in cytosol translocation.
J. Biol. Chem. 263, 1295-1300.
98. Woo JH, Liu YY, Mathias A, Stavrou S, Wang Z, Thompson J,
(2002) Gene optimization is necessary to express a bivalent
anti-human anti-T cell immunotoxin in Pichia pastoris.
Protein Expr. Purif. 25, 270-282.
99. Liu YY, Gordienko I, Mathias A, Ma S, Thompson J, Woo JH,
et al. (2000) Expression of an anti-CD3 single-chain immu-
notoxin with a truncated diphtheria toxin in a mutant CHO
cell line. Protein Expr. Purif. 19, 304-311.
100. Lombardi A, Bursomanno S, Lopardo T, Traini R, Colombatti
M, Ippoliti R. (2010) Pichia pastoris as a host for secretion of
toxic saporin chimeras. FASEB J. 24, 253-265.
101. Liu YY, Woo JH, Neville DM. (2003) Targeted introduction
of a diphtheria toxin resistant mutation into the chromosomal
EF-2 locus of Pichia pastoris and expression of immunotoxin
in the EF-2 mutants. Protein Expr. Purif. 30, 262-274.
102. Woo JH, Liu YY, Stavrou S, Neville DM. Jr. (2004) Increas-
ing secretion of a bivalent anti-T-cell immunotoxin by Pichia
pastoris. Appl. Environ. Microbiol. 70, 3370-3376.
103. Woo JH, Liu YY, Neville DM. Jr. (2006) Minimization of
aggregation of secreted bivalent anti-human T cell immuno-
toxin in Pichia pastoris bioreactor culture by optimizing
culture conditions for protein secretion. J. Biotechnol. 121,
75-85.
104. Williams DP, Snider CE, Strom TB, Murphy JR. (1990)
Structure/function analysis of interleukin-2-toxin
(DAB486-IL-2). Fragment B sequences required for the
delivery of fragment A to the cytosol of target cells.

J. Biol. Chem. 265, 11885-11889.
105. Williams DP, Parker K, Bacha P, Bishai W, Borowski M,
Genbauffe F, et al. (1987) Diphtheria toxin receptor binding
domain substitution with interleukin-2: genetic construction
and properties of a diphtheria toxin-related interleukin-2
fusion protein. Protein Eng. 1, 493-498.
106. Woo JH, Liu JS, Kang SH, Singh R, Park SK, Su Y. (2008)
GMP production and characterization of the bivalent
anti-human T cell immunotoxin, A-dmDT390-bisFv
(UCHT1) for Phase I/II clinical trials. Protein Expr. Purif.
58, 1-11.
107. Woo JH, Neville DM.Jr. (2003) Separation of bivalent anti-T
cell immunotoxin from Pichia pastoris glycoproteins by
borate anion exchange. Biotechniques 35, 392-398.